Malin Corporation Plc is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	€6.250	-9.42%	1,627
22/10/26	€6.900	-0.72%	1,064
21/10/26	€6.950	0.00%	0
20/10/26	€6.950	0.00%	0
19/10/26	€6.950	0.00%	0

Real-time Euronext Dublin

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.250EUR

Average target price

15.50EUR

Spread / Average Target

+148.00%

Consensus

Real-time Euronext Dublin 18:55:00 23/10/2026 +03			5-day change	1st Jan Change
6.250 ^EUR	-9.42%		-10.07%	-18.83%

10-23	Malin Corp writes off investee after US FDA drug rejection	AN
08-26	Malin swings to interim profit as finance income rises and costs fall	AN

Market Cap	27.09M 30.34M 25.03M 22.68M 42.44M 2.88B 43.14M 301M 119M 1.51B 114M 111M 4.76B	P/E 2024 *	-	P/E 2025	-8.37x
Enterprise Value	14.19M 15.9M 13.11M 11.88M 22.23M 1.51B 22.6M 158M 62.47M 791M 59.65M 58.38M 2.49B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	63.83%	Yield 2024 *	-	Yield 2025	-

10-23	Malin Corp writes off investee after US FDA drug rejection	AN
08-26	Malin swings to interim profit as finance income rises and costs fall	AN
02-26	EARNINGS AND TRADING: Connecting Excellence hails record January fees	AN
02-26	Malin Corporation says CEO Fiona Dunlevy will leave Malin end of May	RE
02-26	Malin Corporation plc Announces Departure of Fiona Dunlevy as CEO At End of May	CI
02-26	Malin Corporation plc Announces Executive Changes	CI
02-26	Malin CEO to Step Down; Chair to Take Executive Role	MT
02-26	Malin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
27/08/25	Malin in valuation fall amid Poseida sale, EUR150 million return	AN
21/03/25	Malin completes oversubscribed EUR150 million tender offer	AN
21/03/25	Malin Concludes EUR150 Million Tender Offer	MT
21/03/25	Tranche Update on Malin Corporation plc's Equity Buyback Plan announced on February 19, 2025.	CI
20/03/25	Malin Corporation plc 's Equity Buyback announced on February 19, 2025 has closed with 14,563,106 shares, representing 77.1% for ?150 million.	CI

03-26	Malin : 2026 AGM Voting (2026 AGM Voting Votes for Malin Website)	PU
03-02	Malin : AGM Notice of 2026 Annual General Meeting (MPLC 2026 AGM Notice of AGM FINAL)	PU
03-02	Malin : AGM Form of Proxy (For Information Only) (197908 131OAC 01 WEB)	PU
11-26	Malin : Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women’s Health	PU
11/04/25	Malin : 2024 Information Statements	PU

Malin Corporation Plc Stock

Stocks

MLC

IE00BVGC3741

Pharmaceuticals

Valuation: Malin Corporation Plc

Chart: Malin Corporation Plc

Latest news: Malin Corporation Plc

Press Releases: Malin Corporation Plc

News in other languages: Malin Corporation Plc

Quotes and Performance

Price Extremes

Managers and Directors: Malin Corporation Plc

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

16/08/19	AVIS D'ANALYSTES DU JOUR : Walmart, Nvidia, Amazon, Apple, Uber, Bayer, SAP, Maersk, Roche, Carrefour…
20/03/15	La biotech irlandaise Malin lève 330 mlns avec son IPO
20/03/15	La biotech irlandaise Malin lève 330 mlns avec son IPO

1 day	-9.42%
1 week	-10.07%
Current month	-10.71%
1 month	-10.71%
3 months	-11.97%
6 months	-21.38%
Current year	-18.83%

1 week	6.25	6.95
1 month	6.25	7
Current year	6.25	8.45
1 year	6.25	9.3
3 years	3.84	10.4
5 years	3.59	10.4
10 years	1.4	13.24

Director	Title	Age	Since
William Daniel CHM	Chairman	73	02/08/2019
Jean-Michel Cossery BRD	Director/Board Member	67	16/07/2018
Rudy Mareel BRD	Director/Board Member	63	16/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/2/26 A	Fiona Dunlevy	Exercice		10,307	0.2382%
5/28/25 A	Fiona Dunlevy	Exercice	Chief Executive Officer	5,746	0.1328%
4/7/25 A	Jean-Michel Cossery	Sell	Director	11,075	0.2560%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MALIN CORPORATION PLC	-9.42%	-10.07%	-24.70%	+56.25%	30.34M
ELI LILLY AND COMPANY	+0.36%	+2.83%	+54.33%	+124.51%	1,135B
JOHNSON & JOHNSON	+0.80%	+4.78%	+39.74%	+78.47%	635B
ABBVIE INC.	+0.34%	+1.34%	+25.63%	+97.30%	505B
ROCHE HOLDING AG	+1.32%	+4.10%	+47.98%	+66.79%	378B
MERCK & CO., INC.	-2.07%	-1.41%	+60.92%	+34.16%	358B
NOVARTIS AG	-0.44%	+2.17%	+23.01%	+49.14%	295B
ASTRAZENECA PLC	+0.03%	+3.31%	+2.10%	+23.27%	266B
AMGEN INC.	+0.24%	+3.81%	+51.51%	+63.56%	237B
GILEAD SCIENCES, INC.	+1.66%	+3.40%	+31.38%	+101.62%	193B
Average	-0.71%	+0.43%	+31.19%	+69.51%	400.37B
Weighted average by Cap.	+0.27%	+1.63%	+41.33%	+83.23%

	2024	2025
Net sales	-	-
Net income	-	-6.9M -7.73M -6.37M -5.78M -10.81M -733M -10.99M -76.71M -30.37M -384M -29M -28.38M -1.21B
Net Debt	-62.1M -69.54M -57.37M -51.99M -97.26M -6.6B -98.87M -690M -273M -3.46B -261M -255M -10.9B	-12.9M -14.45M -11.92M -10.8M -20.2M -1.37B -20.54M -143M -56.78M -718M -54.21M -53.06M -2.27B